Visualization analysis of research progress and trends in coexistence of lung cancer and pulmonary tuberculosis using bibliometrics
), Wenping Gong2 
()Graphical Abstract
Abstract
The incidence of lung cancer combined with pulmonary tuberculosis has been increasing, but there is relatively limited published literature on the topic of lung cancer combined with tuberculosis (LC‐PTB) from a bibliometric perspective. Therefore, in this study, we aimed to quantitatively analyze the LC‐PTB‐related literature to better understand the current status of this field and identify future research trends.
We searched for articles related to LC‐PTB using the Web of Science Core Collection (SCI‐E) and conducted a visual analysis of publication quantity, countries, institutions, authors, journals, references, and keywords using bibliometric software (CiteSpace, VOSviewer, and Scimago Graphica).
As of January 8, 2024, a total of 460 publications related to LC‐PTB were included for analysis from 3705 retrieved records. The number of publications has been increasing almost yearly, with most from China (n = 123), followed by the United States (n = 77). Taipei Medical University contributed the most publications (n = 11). Jing‐Yang Huang and Yung‐Po Liaw (eight documents each) ranked first among the included authors. The Journal of Thoracic Oncology was the most productive academic journal on LC‐PTB. The aggregation of key nodes in the co‐citation network and the chronological sequence indicated that LC‐PTB research has shifted from initial hotspots such as lung diseases, bronchitis, and exposure to recent areas, including immunotherapy, immune checkpoint inhibitors, and nivolumab.
In this study, we visualized the current status of LC‐PTB research as well as future trends using bibliometric methods, providing new insights into the differential diagnosis of LC‐PTB and its related promoting mechanisms.
Keywords
Electronic Supplementary Material
References
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. https://doi.org/10.3322/caac.21820
Zheng RS, Zhang SW, Sun KX, Chen R, Wang SM, Li L, et al. Cancer statistics in China, 2016. Zhonghua Zhongliu Zazhi. 2023;45(3):212–20. https://doi.org/10.3760/cma.j.cn112152-20220922-00647
Li LS, Yang L, Zhuang L, Ye ZY, Zhao WG, Gong WP. From immunology to artificial intelligence: revolutionizing latent tuberculosis infection diagnosis with machine learning. Mil Med Res. 2023;10(1):58. https://doi.org/10.1186/s40779-023-00490-8
WHO. Global tuberculosis report 2023. Geneva: World Health Organization; 2023. p. 1–75.
Liang HY, Li XL, Yu XS, Guan P, Yin ZH, He QC, et al. Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review. Int J Cancer. 2009;125(12):2936–44. https://doi.org/10.1002/ijc.24636
Dobler CC, Cheung K, Nguyen J, Martin A. Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta‐analysis. Eur Respir J. 2017;50(2):1700157. https://doi.org/10.1183/13993003.00157-2017
Cheng MP, Abou Chakra CN, Yansouni CP, Cnossen S, Shrier I, Menzies D, et al. Risk of active tuberculosis in patients with cancer: a systematic review and meta‐analysis. Clin Infect Dis. 2017;64(5):635–44. https://doi.org/10.1093/cid/ciw838
Hwang SY, Kim JY, Lee HS, Lee S, Kim D, Kim S, et al. Pulmonary tuberculosis and risk of lung cancer: a systematic review and meta‐analysis. J Clin Med. 2022;11(3):765. https://doi.org/10.3390/jcm11030765
Jiang F, Sun T, Cheng P, Wang J, Gong W. A summary on tuberculosis vaccine development‐where to go? J Pers Med. 2023;13(3):408. https://doi.org/10.3390/jpm13030408
Ninkov A, Frank JR, Maggio LA. Bibliometrics: methods for studying academic publishing. Perspect Med Educ. 2022;11(3):173–6. https://doi.org/10.1007/s40037-021-00695-4
Broadus RN. Toward a definition of “bibliometrics”. Scientometrics. 1987;12(5):373–9. https://doi.org/10.1007/BF02016680
Schreiber K, Girard T, Kindler CH. Bibliometric analysis of original molecular biology research in anaesthesia. Anaesthesia. 2004;59(10):1002–7. https://doi.org/10.1111/j.1365-2044.2004.03873.x
Wang W, Wang H, Yao T, Li Y, Yi L, Gao Y, et al. The top 100 most cited articles on COVID‐19 vaccine: a bibliometric analysis. Clin Exp Med. 2023;23(6):2287–99. https://doi.org/10.1007/s10238-023-01046-9
Ellegaard O, Wallin JA. The bibliometric analysis of scholarly production: how great is the impact? Scientometrics. 2015;105(3):1809–31. https://doi.org/10.1007/s11192-015-1645-z
Kokol P, Blažun Vošner H, Završnik J. Application of bibliometrics in medicine: a historical bibliometrics analysis. Health Info Libr J. 2021;38(2):125–38. https://doi.org/10.1111/hir.12295
Quaia E, Vernuccio F. The H index myth: a form of fanaticism or a simple misconception? Tomography. 2022;8(3):1241–3. https://doi.org/10.3390/tomography8030102
Costas R, Bordons M. The h‐index: advantages, limitations and its relation with other bibliometric indicators at the micro level. J Informetr. 2007;1(3):193–203. https://doi.org/10.1016/j.joi.2007.02.001
Djoutsop OM, Mbougo JV, Kanmounye US. Global head and neck surgery research during the COVID pandemic: a bibliometric analysis. Ann Med Surg. 2021;68:102555. https://doi.org/10.1016/j.amsu.2021.102555
Wolfe AW. Social network analysis: methods and applications. Am Ethnol. 1997;24(1):219–20. https://doi.org/10.1525/ae.1997.24.1.219
Rivera MT, Soderstrom SB, Uzzi B. Dynamics of dyads in social networks: assortative, relational, and proximity mechanisms. Annu Rev Sociol. 2010;36(1):91–115. https://doi.org/10.1146/annurev.soc.34.040507.134743
Pendlebury DA. The use and misuse of journal metrics and other citation indicators. Arch Immunol Ther Exp. 2009;57(1):1–11. https://doi.org/10.1007/s00005-009-0008-y
Casadevall A, Fang FC. Impacted science: impact is not importance. mBio. 2015;6(5):e01593. https://doi.org/10.1128/mBio.01593-15
Garfield E. The history and meaning of the journal impact factor. JAMA. 2006;295(1):90–3. https://doi.org/10.1001/jama.295.1.90
Liu X, Zhao S, Tan L, Tan Y, Wang Y, Ye Z, et al. Frontier and hot topics in electrochemiluminescence sensing technology based on CiteSpace bibliometric analysis. Biosens Bioelectron. 2022;201:113932. https://doi.org/10.1016/j.bios.2021.113932
Xia Y, Yao RQ, Zhao PY, Tao ZB, Zheng LY, Zhou HT, et al. Publication trends of research on COVID‐19 and host immune response: a bibliometric analysis. Front Public Health. 2022;10:939053. https://doi.org/10.3389/fpubh.2022.939053
Xiong M, Xu Y, Zhao Y, He S, Zhu Q, Wu Y, et al. Quantitative analysis of artificial intelligence on liver cancer: a bibliometric analysis. Front Oncol. 2023;13:990306. https://doi.org/10.3389/fonc.2023.990306
Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci USA. 2004;101(Suppl 1):5303–10. https://doi.org/10.1073/pnas.0307513100
van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38. https://doi.org/10.1007/s11192-009-0146-3
Cobo MJ, López‐Herrera AG, Herrera‐Viedma E, Herrera F. Science mapping software tools: review, analysis, and cooperative study among tools. J Am Soc Inf Sci Technol. 2011;62(7):1382–402. https://doi.org/10.1002/asi.21525
Chen C. CiteSpace Ⅱ: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci. 2006;57(3):359–77. https://doi.org/10.1002/asi.20317
Hu Y, Wu L, He L, Luo X, Hu L, Wang Y, et al. Bibliometric and visualized analysis of scientific publications on rehabilitation of rotator cuff injury based on web of science. Front Public Health. 2023;11:1064576. https://doi.org/10.3389/fpubh.2023.1064576
Wei N, Xu Y, Li YN, Shi J, Zhang X, You Y, et al. A bibliometric analysis of T cell and atherosclerosis. Front Immunol. 2022;13:948314. https://doi.org/10.3389/fimmu.2022.948314
Adjei AA. The coming of a new age: the journal of thoracic oncology goes electronic in 2024. J Thorac Oncol. 2023;18(10):1257. https://doi.org/10.1016/j.jtho.2023.08.006
Wang J, Maniruzzaman M. A global bibliometric and visualized analysis of bacteria‐mediated cancer therapy. Drug Discov Today. 2022;27(10):103297. https://doi.org/10.1016/j.drudis.2022.05.023
Shi Y, Wei W, Li L, Wei Q, Jiang F, Xia G, et al. The global status of research in breast cancer liver metastasis: a bibliometric and visualized analysis. Bioengineered. 2021;12(2):12246–62. https://doi.org/10.1080/21655979.2021.2006552
Liu K, Zhao S, Li J, Zheng Y, Wu H, Kong J, et al. Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: a text‐mining study from 2002 to 2021. Front Immunol. 2022;13:969217. https://doi.org/10.3389/fimmu.2022.969217
Jiang F, Su Y, Chang T. Knowledge mapping of global trends for myasthenia gravis development: a bibliometrics analysis. Front Immunol. 2023;14:1132201. https://doi.org/10.3389/fimmu.2023.1132201
Yu YH, Liao CC, Hsu WH, Chen HJ, Liao WC, Muo CH, et al. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol. 2011;6(1):32–7. https://doi.org/10.1097/JTO.0b013e3181fb4fcc
Fujita K, Terashima T, Mio T. Anti‐PD1 antibody treatment and the development of acute pulmonary tuberculosis. J Thorac Oncol. 2016;11(12):2238–40. https://doi.org/10.1016/j.jtho.2016.07.006
Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM, et al. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD‐1 treatment. Clin Microbiol Infect. 2018;24(3):216–8. https://doi.org/10.1016/j.cmi.2017.12.003
Wu CY, Hu HY, Pu CY, Huang N, Shen HC, Li CP, et al. Pulmonary tuberculosis increases the risk of lung cancer: a population‐based cohort study. Cancer. 2011;117(3):618–24. https://doi.org/10.1002/cncr.25616
Anastasopoulou A, Ziogas DC, Samarkos M, Kirkwood JM, Gogas H. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer. 2019;7(1):239. https://doi.org/10.1186/s40425-019-0717-7
Chu YC, Fang KC, Chen HC, Yeh YC, Tseng CE, Chou TY, et al. Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti‐PD‐1 treatment in a patient with advanced pulmonary adenocarcinoma. J Thorac Oncol. 2017;12(8):e111–4. https://doi.org/10.1016/j.jtho.2017.03.012
Barber DL, Sakai S, Kudchadkar RR, Fling SP, Day TA, Vergara JA, et al. Tuberculosis following PD‐1 blockade for cancer immunotherapy. Sci Transl Med. 2019;11(475):eaat2702. https://doi.org/10.1126/scitranslmed.aat2702
Ho JCM, Leung CC. Management of co‐existent tuberculosis and lung cancer. Lung Cancer. 2018;122:83–7. https://doi.org/10.1016/j.lungcan.2018.05.030
Elkington PT, Bateman AC, Thomas GJ, Ottensmeier CH. Implications of tuberculosis reactivation after immune checkpoint inhibition. Am J Respir Crit Care Med. 2018;198(11):1451–3. https://doi.org/10.1164/rccm.201807-1250LE
Sheikhpour M, Mirbahari SN, Sadr M, Maleki M, Arabi M, Abolfathi H. A comprehensive study on the correlation of treatment, diagnosis and epidemiology of tuberculosis and lung cancer. Tanaffos. 2023;22(1):7–18.
Bordignon V, Bultrini S, Prignano G, Sperduti I, Piperno G, Bonifati C, et al. High prevalence of latent tuberculosis infection in autoimmune disorders such as psoriasis and in chronic respiratory diseases, including lung cancer. J Biol Regul Homeost Agents. 2011;25(2):213–20.
Li Z. The value of GeneXpert MTB/RIF for detection in tuberculosis: a bibliometrics‐based analysis and review. J Anal Methods Chem. 2022;2022:2915018–111. https://doi.org/10.1155/2022/2915018
Pan Y, Deng X, Zhuang Y, Li J. Research trends around exercise rehabilitation among cancer patients: a bibliometrics and visualized knowledge graph analysis. BioMed Res Int. 2022;2022:3755460–511. https://doi.org/10.1155/2022/3755460
Gandhi L, Rodríguez‐Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non‐small‐cell lung cancer. N Engl J Med. 2018;378(22):2078–92. https://doi.org/10.1056/NEJMoa1801005
Paz‐Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non‐small‐cell lung cancer. N Engl J Med. 2018;379(21):2040–51. https://doi.org/10.1056/NEJMoa1810865
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD‐L1‐expressing, locally advanced or metastatic non‐small‐cell lung cancer (KEYNOTE‐042): a randomised, open‐label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30. https://doi.org/10.1016/S0140-6736(18)32409-7
Johnson EO, LaVerriere E, Office E, Stanley M, Meyer E, Kawate T, et al. Large‐scale chemical‐genetics yields new M. tuberculosis inhibitor classes. Nature. 2019;571(7763):72–8. https://doi.org/10.1038/s41586-019-1315-z
Brenner AV, Wang Z, Kleinerman RA, Wang L, Zhang S, Metayer C, et al. Previous pulmonary diseases and risk of lung cancer in Gansu Province, China. Int J Epidemiol. 2001;30(1):118–24. https://doi.org/10.1093/ije/30.1.118
Gong W, Liang Y, Wu X. The current status, challenges, and future developments of new tuberculosis vaccines. Hum Vaccin Immunother. 2018;14(7):1697–716. https://doi.org/10.1080/21645515.2018.1458806
Zhuang L, Ye Z, Li L, Yang L, Gong W. Next‐generation TB vaccines: progress, challenges, and prospects. Vaccines. 2023;11(8):1304. https://doi.org/10.3390/vaccines11081304
HosgoodIII HD, Chapman RS, He X, Hu W, Tian L, Liu LZ, et al. History of lung disease and risk of lung cancer in a population with high household fuel combustion exposures in rural China. Lung Cancer. 2013;81(3):343–6. https://doi.org/10.1016/j.lungcan.2013.06.019
Du J, Su Y, Qiao J, Gao S, Dong E, Wang R, et al. Application of artificial intelligence in diagnosis of pulmonary tuberculosis. Chin Med J. 2024;137(5):559–61. https://doi.org/10.1097/CM9.0000000000003018
Yang L, Zhuang L, Ye Z, Li L, Guan J, Gong W. Immunotherapy and biomarkers in patients with lung cancer with tuberculosis: recent advances and future Directions. iScience. 2023;26(10):107881. https://doi.org/10.1016/j.isci.2023.107881
King DA. The scientific impact of nations. Nature. 2004;430(6997):311–6. https://doi.org/10.1038/430311a
Talukdar T, Rathi V, Ish P. Geriatric tuberculosis in India‐challenges and solutions. Indian J Tuberc. 2022;69(Suppl 2):S209–12. https://doi.org/10.1016/j.ijtb.2022.10.003
Rallison SP. What are journals for? Ann R Coll Surg Engl. 2015;97(2):89–91. https://doi.org/10.1308/003588414X14055925061397
Suzuki K, Edelson A, Iversen LL, Hausmann L, Schulz JB, Turner AJ. A learned society’s perspective on publishing. J Neurochem. 2016;139(Suppl 2):17–23. https://doi.org/10.1111/jnc.13674
Shen C, Björk BC. Predatory’ open access: a longitudinal study of article volumes and market characteristics. BMC Med. 2015;13(1):230. https://doi.org/10.1186/s12916-015-0469-2
Cheng K, Zhang H, Guo Q, Zhai P, Zhou Y, Yang W, et al. Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: a bibliometric study. Front Immunol. 2022;13:975695. https://doi.org/10.3389/fimmu.2022.975695
Wu X, Deng Z, Zhao Q. Immunotherapy improves disease prognosis by affecting the tumor microenvironment: a bibliometric study. Front Immunol. 2022;13:967076. https://doi.org/10.3389/fimmu.2022.967076
Anichini A, Perotti VE, Sgambelluri F, Mortarini R. Immune escape mechanisms in non small cell lung cancer. Cancers. 2020;12(12):3605. https://doi.org/10.3390/cancers12123605
WHO. Framework for conducting reviews of tuberculosis programmes. Geneva: World Health Organization; 2014.
Kim HR, Hwang SS, Ro YK, Jeon CH, Ha DY, Park SJ, et al. Solid‐organ malignancy as a risk factor for tuberculosis. Respirology. 2008;13(3):413–9. https://doi.org/10.1111/j.1440-1843.2008.01282.x
Peng C, Jiang F, Liu Y, Xue Y, Cheng P, Wang J, et al. Development and evaluation of a promising biomarker for diagnosis of latent and active tuberculosis infection. Infect Dis Immun. 2024;4(1):10–24. https://doi.org/10.1097/id9.0000000000000104
Xie Y, Su N, Zhou W, Lei A, Li X, Li W, et al. Concomitant pulmonary tuberculosis impair survival in advanced epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma patients receiving EGFR‐tyrosine kinase inhibitor. Cancer Manag Res. 2021;13:7517–26. https://doi.org/10.2147/CMAR.S326349
Liu N, Zheng L, Yu M, Zhang S. Epidermal growth factor receptor‐mutant pulmonary adenocarcinoma coexisting with tuberculosis: a case report. Medicine (Baltim). 2021;100(8):e24569. https://doi.org/10.1097/MD.0000000000024569
George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, et al. Loss of PTEN is associated with resistance to anti‐PD‐1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity. 2017;46(2):197–204. https://doi.org/10.1016/j.immuni.2017.02.001
Huang G, Redelman‐Sidi G, Rosen N, Glickman MS, Jiang X. Inhibition of mycobacterial infection by the tumor suppressor PTEN. J Biol Chem. 2012;287(27):23196–202. https://doi.org/10.1074/jbc.M112.351940
Yang Y, Yang L, Wang Y. Immunotherapy for lung cancer: mechanisms of resistance and response strategy. Zhongguo Fei Ai Za Zhi. 2021;24(2):112–23. https://doi.org/10.3779/j.issn.1009-3419.2021.101.02
Keikha M, Esfahani BN. The relationship between tuberculosis and lung cancer. Adv Biomed Res. 2018;7(1):58. https://doi.org/10.4103/abr.abr_182_17
Xiao F, Li C, Sun J, Zhang L. Knowledge domain and emerging trends in organic photovoltaic technology: a scientometric review based on CiteSpace analysis. Front Chem. 2017;5:67. https://doi.org/10.3389/fchem.2017.00067
Ma L, Ma J, Teng M, Li Y. Visual analysis of colorectal cancer immunotherapy: a bibliometric analysis from 2012 to 2021. Front Immunol. 2022;13:843106. https://doi.org/10.3389/fimmu.2022.843106
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor‐infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–21. https://doi.org/10.1038/s41423-020-0488-6
Okwundu N, Grossman D, Hu‐Lieskovan S, Grossmann KF, Swami U. The dark side of immunotherapy. Ann Transl Med. 2021;9(12):1041. https://doi.org/10.21037/atm-20-4750
Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol. 2018;18(2):91–104. https://doi.org/10.1038/nri.2017.112
Dhar C. Testing for latent tuberculosis before starting patients on immune checkpoint inhibitors. Indian J Cancer. 2021;58(3):469–70. https://doi.org/10.4103/ijc.IJC_283_20
Waltman L, van Eck NJ. Source normalized indicators of citation impact: an overview of different approaches and an empirical comparison. Scientometrics. 2013;96(3):699–716. https://doi.org/10.1007/s11192-012-0913-4
京公网安备11010802044758号